Roche's Genentech defends supply shift for top cancer drugs
November 24, 2014 at 18:35 PM EST
Nov 24 (Reuters) - Genentech, U.S. biotech unit of Roche Holding, faces growing pressure over a decision to allow only a handful of distributors to supply three of the world's most widely used cancer drugs, a move that prominent hospitals say will create delays and raise costs.